|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1997-6-16
|
|
pubmed:abstractText |
Dolasetron is a 5-HT3 antagonist antiemetic with active oral and intravenous formulations. The effects of this class are enhanced when combined with dexamethasone. This study tested the ability of the combination of oral dolasetron 200 mg and oral dexamethasone 20 mg to prevent acute emesis in cancer patients receiving initial cisplatin at doses > or = 70 mg/m2. Additionally, patients were randomly assigned to receive a second dosage of the regimen 16 hours later to improve control of acute symptoms.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:AllmanD SDS,
pubmed-author:BakerT WTW,
pubmed-author:ChernoffS BSB,
pubmed-author:FergusonB BBB,
pubmed-author:FernandoI JIJ,
pubmed-author:GroteT HTH,
pubmed-author:KrisM GMG,
pubmed-author:NavariR MRM,
pubmed-author:NelsonA MAM,
pubmed-author:PendergrassK BKB,
pubmed-author:PizzoB ABA,
pubmed-author:ThomasVV
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2135-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9164228-Acute Disease,
pubmed-meshheading:9164228-Administration, Oral,
pubmed-meshheading:9164228-Antiemetics,
pubmed-meshheading:9164228-Antineoplastic Agents,
pubmed-meshheading:9164228-Cisplatin,
pubmed-meshheading:9164228-Dexamethasone,
pubmed-meshheading:9164228-Drug Therapy, Combination,
pubmed-meshheading:9164228-Female,
pubmed-meshheading:9164228-Humans,
pubmed-meshheading:9164228-Indoles,
pubmed-meshheading:9164228-Male,
pubmed-meshheading:9164228-Middle Aged,
pubmed-meshheading:9164228-Nausea,
pubmed-meshheading:9164228-Neoplasms,
pubmed-meshheading:9164228-Quinolizines,
pubmed-meshheading:9164228-Vomiting
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.
|
|
pubmed:affiliation |
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. krism@mskcc.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
